

HISTORICALLY ACCEPTED USE

Tertiary and Quaternary Committee

Executive Summary

Date: Medicine (INN): Medicine (ATC): Indication/s (ICD10 code/s): Patient population/s: Prevalence of condition/s: Level of Care: Prescriber Level: Current standard of Care: Efficacy estimates:

Historically accepted use Criteria

Criteria		Comment	
1	The medicine is included in the WHO Model Essential Medicines List, either as a core or complementary item, for the indication requested.	YES <input type="checkbox"/>	NO <input type="checkbox"/>
2	The medicine is currently registered by SAHPRA for the indication.	YES <input type="checkbox"/>	NO <input type="checkbox"/>
3	There is evidence of long-established (prior to 1996*) safe and effective use of the medicine for the recognised indication in the public health sector.	YES <input type="checkbox"/>	NO <input type="checkbox"/>
		Comment:	
4	There are no new safety or efficacy concerns.	YES <input type="checkbox"/>	NO <input type="checkbox"/>
		Comment:	
5	The budget impact is not expected to have an incremental increase, that a de novo review is justified.	YES <input type="checkbox"/>	NO <input type="checkbox"/>
		Comment:	
6	Equitable access across the country is essential, and is limited only by the availability of adequately trained staff and availability of equipment.	YES <input type="checkbox"/>	NO <input type="checkbox"/>
		Comment:	

* The Essential Drugs Programme (EDP) of South Africa was established in terms of the National Drug Policy (NDP) which was implemented in 1996

Recommendation

--